Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins

• Главные авторы: Xiao-Qin Liu (Автор), Hong-Yi Xin (Автор), Yan-Ning Lyu (Автор), Zhao-Wu Ma (Автор), Xiao-Chun Peng (Автор), Ying Xiang (Автор), Ying-Ying Wang (Автор), Zi-Jun Wu (Автор), Jun-Ting Cheng (Автор), Jia-Fu Ji (Автор), Ji-Xin Zhong (Автор), Bo-Xu Ren (Автор), Xian-Wang Wang (Автор), Hong-Wu Xin (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and...